For many grappling with the chronic conditions of multiple sclerosis (MS), muscle spasticity remains a resilient adversary, hindering movement and clouding one's quality of life with persistent pain. But a glimmer of hope shines from the University of Cincinnati Gardner Neuroscience Institute, as they step forward to trial a new oral drug potentially poised to shift the treatment paradigm. The trial's objective is bold yet simple - to harness, and to subtly elevate, the body's innate healing mechanisms.
Treatment options for MS-related spasticity have historically been a patchwork of medications and physical interventions, yet often come bundled with undesirable side effects like drowsiness. The new drug seeks to change that by inhibiting enzymes responsible for breaking down endocannabinoids – the body's natural muscle relaxers. According to the University of Cincinnati, this could lead to a more effective treatment with less impact on patients' daily functioning.
Moving into clinical trials, their focus is on a compound designed to raise levels of endocannabinoids, which have been found lacking in those with MS. "The majority of the currently available oral medications have side effects like drowsiness, which limits their usefulness during the daytime, and so we really need a new effective treatment for spasticity that’s better tolerated by patients," Shahla Hosseini, MD, PhD, told the University of Cincinnati, laying bare the need for innovation in this space.
Around 200 participants across various locations will be enrolled in this international, multicenter Phase 2 trial. They will randomly be given one of three doses of the trial drug or a placebo, daily over six weeks. There's an optional extension for another six weeks, designed exclusively to test the three different doses against each other in treating spasticity, ensuring all participants a chance to try the active drug. If successful, the trial could be a precursor to widely offering a new tool for clinicians to use alongside existing treatments like physiotherapy and botulinum toxin injections.
The implications stretch beyond MS, as spasticity also afflicts those with other neurological conditions involving the brain or spinal cord. The success of this trial could therefore ripple out, offering a new lifeline for a broader demographic of patients shadowed by similar neurological challenges.
